RecruitingPhase 1NCT06504290

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

Studying Cap myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vigonvita Life Sciences
Principal Investigator
Gang Wang
Beijing Anding Hospital of Capital Medical University
Intervention
VV119 Placebo (in healthy adult subjects)(drug)
Enrollment
40 enrolled
Eligibility
18-65 years · All sexes
Timeline
20242026

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06504290 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy

← Back to all trials